- No public price.
- Not disclosed
- Not disclosed
- —
- 2018
- US
Pathology
Mirvie
by Mirvie · founded 2018 · US
Encompass blood test: an RNA signature that estimates preeclampsia risk in pregnancy. Ordered online with telehealth approval.
On this page
23/100
Not rated: too little independent evidence yet.
- Regulatory & Compliance0/28
No FDA clearance listed
- Clinical Integration0/6.6
No EHR integrations listed
- Evidence Strength8.4/28.8
1 peer-reviewed paper
- Vendor & Market9/18
Founded 2018 (8 years)
- Sentiment & Transparency2.5/5
Pricing on request, no public amounts
▸ Show all 11 dimensions▾ Hide dimension detail
- FDA clearance0/18
No FDA clearance listed
- HIPAA / SOC2 / BAA0/10
No public HIPAA/SOC2/BAA attestation
- EHR integrations (count)0/4
No EHR integrations listed
- Top-3 EHR coverage (Epic / Oracle / Athena)0/2
None of the top-3 EHRs covered
- Peer-reviewed papers8/21
1 peer-reviewed paper
- RCT / meta-analysis / systematic review0/8
No RCT, meta-analysis, or systematic review
- Funding & adoption signal3/12
Seed-stage or unfunded
- Years in market6/6
Founded 2018 (8 years)
- Pricing transparency3/5
Pricing on request, no public amounts
Encompass blood test: an RNA signature that estimates preeclampsia risk in pregnancy. Ordered online with telehealth approval.
No public price.
Evidence record
No FDA decision cited in our research as of November 2, 2026.
1 study on PubMed: 1 other, published 2022. Read the literature summary
- Score computed November 2, 2026, method 1.2.0
- Review written November 2, 2026
MedAI Verdict, Mirvie record, https://medaiverdict.com/tools/mirvie, version November 2, 2026
Bottom line
Mirvie's Encompass is a blood test that estimates preeclampsia risk, ordered at encompasstest.com and approved by a licensed telehealth provider. It launched on May 14, 2025 and is available in the US except New York. Eligibility is 35 or older at delivery with no pre-existing high-risk conditions, so younger patients and those with such conditions sit outside it, and the release says physician-office access is planned. The Encompass release makes no FDA or CLIA statement, and Mirvie announced an FDA Breakthrough Device designation in May 2022.
How does a patient get Encompass?
The patient orders online and the telehealth provider approves the order. A home blood draw takes place at 18 to 22 weeks, and results arrive in 10 to 14 days. The package includes a preventive plan and a virtual assistant. The test scores a cell-free RNA signature from maternal blood for preterm preeclampsia risk, and Mirvie says its RNA platform predicts pregnancy complications months before they occur.
What accuracy does Mirvie claim?
The vendor cites a study of nearly 11,000 US pregnancies. According to Mirvie, the test flagged 9 of 10 patients who later developed preterm preeclampsia as high risk, and a low-risk result carried a 99.7% probability of not developing it. A release of April 8, 2025 calls the work the largest molecular study in pregnancy and clinical validation.
Mirvie-authored papers include a 2022 Nature paper on RNA profiles that carry signatures of future health and disease in pregnancy and a 2025 Nature Communications paper on molecular subtyping of hypertensive disorders of pregnancy. A 2026 budget impact model of a cell-free RNA test-and-treat strategy for preeclampsia also has a Mirvie author. No independent external validation of Encompass appears in the PubMed results.
What else is Mirvie researching?
The same platform has produced Mirvie-authored work on preterm birth, including a 2022 American Journal of Obstetrics and Gynecology paper on predictive RNA profiles for early and very early spontaneous preterm birth and a 2024 Clinics in Perinatology paper. In January 2025 Mirvie reported a signal for severe fetal growth restriction. A 2024 survey paper in BMC Pregnancy and Childbirth asks how early preeclampsia prediction might change adherence and behavior.
What does Mirvie say about funding and cost?
Mirvie announced a $60M Series B on May 17, 2022, led by Decheng Capital, and put its raised total at more than $90 million as of that date. The homepage and the Encompass release leave price out.
The verdict
The order path decides who Encompass reaches. A patient aged 35 or older with no pre-existing high-risk condition orders online and a telehealth provider approves. An obstetric office waits for the physician-office access the release says is planned. A buyer who wants validation from outside the company has Mirvie's own study of nearly 11,000 pregnancies to rely on.
Editorial review last generated November 2, 2026. Synthesized from clinician sentiment, peer-reviewed coverage, and our editorial silo picks. Refined by hand where vendor facts change.
What it costs
All tiers are custom-quoted. The vendor does not publish per-provider list pricing.
| Tier | Monthly | Annual | Notes |
|---|---|---|---|
| Enterprise | Not stated | Not stated | No public price. |
Source: vendor pricing page. Last checked November 2, 2026.
Who builds it
Mirvie (Mirvie) was founded in 2018 in US, putting it 8 years into market.
What the literature says
1 peer-reviewed study indexed on PubMed evaluate Mirvie in clinical contexts. The most relevant are shown below, ranked by editorial relevance score combining title match, study design, recency, and journal tier.
- Predictive RNA profiles for early and very early spontaneous preterm birth. (opens in new tab)
- Camunas-Soler J, Gee EPS, Reddy M, et al.· Am J Obstet Gynecol· 2022
- Spontaneous preterm birth remains the main driver of childhood morbidity and mortality. Because of an incomplete understanding of the molecular pathways that result in spontaneous preterm birth, accurate predictive markers and target therapeutics remain elusive. This study sought to determine if a cell-free RNA profile could reveal a molecular signature in maternal blood months before the onset of spontaneous preterm birth. Maternal samples (n=242) were obtained from a prospective cohort of individuals with a singleton pregnancy across 4 clinical sites at 12-24 weeks (nested case-control; n=4…
Other pathology
See the full pathology ranking
Tempus Digital Pathology
by Tempus AI
Digital pathology AI from Paige, now part of Tempus: Paige Prostate Detect (FDA De Novo, CE-IVDR) plus research-use suites.
No public price on the Tempus pages.|FDA De Novo (DEN200080) / FDA 510(k) (FullFocus viewer)
PathAI AISight
by PathAI
Cloud image management for digital pathology with AISight Dx, cleared for primary diagnosis, plus biopharma AI services.
No public price. Billing period, trial and refund not stated.|FDA 510(k)
Proscia Concentriq
by Proscia
Concentriq pathology platform for clinical labs and biopharma: image management, case review and AI apps, with FDA-cleared AP-Dx for primary diagnosis.
No public price. Demo request only.|FDA 510(k) / SOC 2 Type II (vendor announcement, 2025-12-03)
Ibex Medical Analytics
by Ibex
AI pathology software for prostate, breast and gastric cancer. One US FDA 510(k) clearance, for prostate.
No public price. Sold to laboratories and health systems on enterprise contracts.|FDA 510(k)